Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03768336 · ClinicalTrials.gov registry record · NA

A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors

A NA study of Cancer, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
72
Enrollment target
1
Study location

NCT03768336: Active NA study of Cancer, sponsored by Massachusetts General Hospital.

NCT03768336 is a NA study of Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 72 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03768336, a NA study of Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
72 participants
Enrollment target
1
Study location

Study Summary

This research study aims to explore the feasibility and acceptability of an adapted resiliency group program, called the Relaxation Response Resiliency Program (3RP-AYA), to reduce stress and promote stress-management among adolescents and young adults who have completed treatment for cancer.

Conditions Studied

Interventions

  • OTHER Waitlist control
  • OTHER 3RP-AYA

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2019-04-01
Est. Completion 2025-08-01
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT03768336

The ClinicalTrials.gov registry entry for NCT03768336 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Waitlist control is the first listed.

NCT03768336 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03768336 about?

NCT03768336 is a clinical study titled "A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors". This research study aims to explore the feasibility and acceptability of an adapted resiliency group program, called the Relaxation Response Resiliency Program (3RP-AYA), to reduce stress and promote stress-management among adolescents and young adults who have completed treatment for cancer.

What is the current status of trial NCT03768336?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 72 participants. The study started on 2019-04-01. Estimated completion is 2025-08-01.

What conditions does trial NCT03768336 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT03768336?

The interventions under investigation include: Waitlist control (OTHER), 3RP-AYA (OTHER).

Who is sponsoring clinical trial NCT03768336?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03768336 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.